Dr. Gail McIntyre, CEO of Aravive, Inc., discusses the urgent need for improved therapeutic approaches to treat patients with ovarian cancer who are resistant to standard of care therapy and have limited treatment options. She explains the challenges with current treatment therapies and talks about Aravive’s lead product candidate, AVB-500, a unique and promising treatment approach for platinum resistant ovarian cancer.The company expects to initiate a pivotal trial during the first quarter of 2021.
Gail McIntyre, Ph.D., is a seasoned biopharma executive with more than 25 years of experience, and currently serves as Aravive, Inc.’s Chief Executive Officer. Having brought multiple drugs to market, Dr. McIntyre’s drug development expertise spans multiple disciplines and therapeutic areas, as well as strategic business development, licensing and M&A. Dr. McIntyre has authored more than 30 regulatory submissions. Her experience covers therapeutic areas such as oncology (including immune-oncology), infectious diseases, central nervous system, gastrointestinal, and metabolic/endocrine as well as various therapeutic modalities including small molecules, treatment vaccines, antibodies, immunoconjugates and peptide mimetics. Dr. McIntyre is a board-certified toxicologist and board certified in Clinical Pathology (hematology and clinical chemistry) by the American Society of Clinical Pathology. Dr. McIntyre received her B.A. in Biology from Merrimack College. She earned M.S. and Ph.D. degrees in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill.